Tot Biopharm International Co., Ltd. (1875)

Overview

TOT BIOPHARM International Company Limited is a notable investment holding entity primarily focused on the discovery, development, manufacturing, and distribution of anti-tumor drugs within China. Incorporated in 2009 and headquartered in Suzhou, China, the company has dedicated its efforts to advancing the treatment of various cancers through innovative therapeutic solutions. Its commitment to research and development in the oncology sector reflects in its broad pipeline of products targeting a range of cancers, employing the latest in medical research and technologies to address the complex challenges of cancer treatment.

Products and Services

• TAB008
  

  This product is developed for the treatment of non-squamous non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, fallopian tube cancer, or primary peritoneal cancer, and hepatocellular carcinoma. TAB008 represents the company's focus on addressing a wide array of cancer types with a single therapeutic solution.

• TOZ309
  

  Specifically designed for the treatment of glioblastoma multiforme or anaplastic astrocytoma, TOZ309 is part of TOT BIOPHARM's dedication to combatting brain cancers. Its development underscores the company's expertise in targeting challenging cancer manifestations with innovative approaches.

• TAA013
  

  Developed for patients with HER2+ breast cancer, TAA013 is a testament to the company's commitment to fighting breast cancer. By focusing on HER2-positive types, TOT BIOPHARM aims to offer a targeted therapeutic option for a specific subset of breast cancer patients.

• TAE020
  

  This preclinical trial candidate is being explored as a treatment for acute myeloid leukemia. TAE020 illustrates the company's effort in extending its research and development to blood cancers, showcasing a diversification of their oncological portfolio.

• TAB014
  

  Directed at addressing wet age-related macular degeneration, TAB014 marks a unique addition to the company's product lineup, showing TOT BIOPHARM's engagement not just in oncology but also in conditions leading to significant visual impairment and blindness.

• TAC020
  

  Developed for the treatment of various solid tumors, TAC020 embodies the company's versatile approach to cancer treatment. It highlights TOT BIOPHARM's commitment to developing broad-spectrum antitumor agents capable of confronting multiple types of solid cancers.